This site is intended for US Healthcare Professionals only
During this time, we understand that access to Axumin PET/CT scans in hospitals may be challenging in some U.S. locations due to COVID-19, especially for vulnerable patients including those who are immunocompromised. In the Axumin Imaging Center Location Directory, hospitals are noted with the following icon:
We suggest contacting the imaging centers in your local area to confirm the ability to schedule a PET/CT scan as well as confirm compliance with the Centers for Disease Control and Prevention (CDC) COVID-19 guidelines, as well as any applicable local and state guidelines.
The imaging centers and physicians included in this list are those who have given their consent to be identified. It is not an exhaustive or complete list of all sites that offer imaging services using Axumin. This information is provided as a reference for referring physicians and is not intended to be an endorsement by Blue Earth Diagnostics, Inc. (BED) of the physicians or sites listed, nor is it an endorsement of BED by those sites. It is the responsibility of the referring physician to determine whether Axumin is the right option for their patients and to identify an appropriate referral site if Axumin is not available at their location.
Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.
Please see Axumin full Prescribing Information.